GelTex, Genzyme announce FDA marketing approval for RenaGel capsules

被引：0

|

作者：

不详

机构：

来源：

DIALYSIS & TRANSPLANTATION | 1999年 / 28卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

引用

收藏

页码：9 / 9

页数：1

相关论文

共 25 条

[1] Genzyme general, GelTex announce European marketing approval for Renagel
不详
[J]. DIALYSIS & TRANSPLANTATION, 2000, 29 (04) : 170 - 171
[2] Renagel - New tablet form, other label changes - Sevelamer HCl tablets - GelTex/Genzyme
不详
[J]. FORMULARY, 2000, 35 (09) : 716 - 716
[3] GelTex NDA for RenaGel non-absorbed phosphate binder accepted as filable by FDA
不详
[J]. DIALYSIS & TRANSPLANTATION, 1998, 27 (03) : 130 - +
[4] American Kidney Fund, Genzyme announce new medicare Part D Assistance Program for Renagel
不详
[J]. DIALYSIS & TRANSPLANTATION, 2006, 35 (11) : 657 - 657
[5] GelTex and genzyme report positive preliminary results of extended-use clinical trial of RenaGel non-absorbed phosphate binder
不详
[J]. DIALYSIS & TRANSPLANTATION, 1998, 27 (09) : 535 - +
[6] Genzyme's Seprafilm gets FDA marketing nod
Kling, J
[J]. NATURE BIOTECHNOLOGY, 1996, 14 (05) : 572 - 572
[7] Withdrawing FDA Approval of Midodrine After Marketing
Holtzman, Neil A.
Starfield, Barbara
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08): : 781 - 782
[8] FDA grants final marketing approval for Corlopam
不详
[J]. DRUG NEWS & PERSPECTIVES, 1997, 10 (08) : 482 - 482
[9] US FDA scientists point to gaps in approval, marketing
[J]. Reactions Weekly, 2005, 1034 (1) : 4 - 4
[10] Withdrawing FDA Approval of Midodrine After Marketing Reply
Dhruva, Sanket S.
Redberg, Rita F.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08): : 782 - 782